Fig. 6

Correlation between six clinical drugs treated response and RUNX1 expression levels in ovarian cancer. RUNX1 expression levels in patients who responded to six clinical ovarian cancer agents versus patients who did not respond (A). Patients who responded to Avastin, paclitaxel, taxane, and platinum agents (cisplatin) had significantly lower levels of RUNX1 expression than those who did not respond. AUC and p-value of ROC of RUNX1 low expression level in treatment with clinical drugs (B, C, D, and E). There was no significant difference in RUNX1 expression between patients who responded to gemcitabine and docetaxel and those who did not reply (F and G). Effects on stably transfected sh-RUNX1 cell lines' proliferation after treatment with paclitaxel, taxane, and cisplatin (H and I). *p < 0.05, **p < 0.01 and ***p < 0.001 as compared with control cells expressing a scramble shRNA control, paired t test